As shown in table 2, both OS and CBR values were in line or higher than those reported in the treatment arm of the ASCENT ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Merck’s combo of KEYTRUDA and Trodelvy reduces disease progression or death risk by 35% in tough-to-treat breast cancer.

Germany's financial regulator BaFin is using artificial intelligence to help it spot market abuse and suspicious patterns in ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...